News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Roche’s EPO Fails To Help Heart Attack Victims In Study
March 30, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ORLANDO, Fla., March 30 (Reuters) - High doses of erythropoietin, which boosts red blood cells, failed to improve the heart's pumping function in a study of heart attack victims, while its use also raised safety concerns.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Roche
MORE ON THIS TOPIC
Obesity
Protagonist Enters Obesity Fray With Triple-G Pill, Eyeing 2026 Clinical Start
July 1, 2025
·
2 min read
·
Tristan Manalac
Lymphoma
Pfizer Ends Mid-Stage Trial for CD47 Blood Cancer Drug, Citing Recruitment Problems
July 1, 2025
·
2 min read
·
Tristan Manalac
Cancer
Amgen’s Antibody Improves Overall Survival in Phase III Gastric Cancer Test
June 30, 2025
·
2 min read
·
Dan Samorodnitsky
Alzheimer’s disease
INmune Crashes After Missing Cognitive Target in Phase II Alzheimer’s Trial
June 30, 2025
·
2 min read
·
Tristan Manalac